<DOC>
	<DOCNO>NCT01441232</DOCNO>
	<brief_summary>This study intend evaluate pharmacodynamics , safety , tolerability LX4211 administer concurrently sitagliptin ( Januvia® ) patient Type 2 Diabetes Mellitus .</brief_summary>
	<brief_title>A Study Evaluate Pharmacodynamic Effects Single-Dose Co-Administration LX4211 With Januvia® Type 2 Diabetics</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Adults age 18 65 year age History Type 2 Diabetes Mellitus least 3 month prior Screening , HgbA1c value 6.5 10.5 % Cpeptide ≥1.0 ng/mL Body mass index ( BMI ) ≤45 kg/sq Willing able selfmonitor blood glucose Able provide write informed consent History Type 1 diabetes mellitus , diabetic ketoacidosis , hyperosmolar nonketotic syndrome , diabetes result pancreatic disorder secondary diabetes Current use blood glucose lower agent metformin History renal disease clinically significant abnormal kidney function test Screening Day 2 Presence active hepatic disease clinically significant abnormal liver function test Screening Day 2 History myocardial infarction , severe/unstable angina , coronary revascularization procedure within 6 month Day 2 History clinically significant cardiac arrhythmia within 1 year Day 2 Congestive heart failure and/or New York Heart Association ( NYHA ) class III IV symptom heart failure Subjects uncontrolled Stage 3 hypertension History 2 emergency room visit , doctor 's visit , hospitalization due hypoglycemia within 6 month Day 2 History alcohol drug abuse within 12 month Screening History bowel resection &gt; 20 cm , malabsorptive disorder , severe gastroparesis , GI procedure purpose weight loss would slow gastric empty History HIV hepatitis C Major surgery within 3 month Day 2 plan surgery study History active infection within 2 week Day 2 History pancreatitis History malignancy within last 5 year would affect diagnosis assessment LX4211 sitagliptin History serious adverse reaction hypersensitivity LX4211 sitagliptin Presence clinically significant physical , laboratory , ECG find concurrent condition Screening may interfere study opinion investigator Triglycerides &gt; 1000 mg/dL Screening Day 2 Donation loss &gt; 400 mL blood blood product within 8 week prior Day 2 Use tobacco product duration study participation Use corticosteroid within 2 week Day 1 Use digoxin warfarin within 2 week prior Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>